Pharming Group NV PHAR.OQ, PHAR.O is expected to show a fall in quarterly revenue when it reports results on March 13 for the period ending December 31 2024
The Leiden Zuid-holland-based company is expected to report a 0.6% decrease in revenue to $80.743 million from $81.22 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Pharming Group NV is for earnings of 1 cent per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pharming Group NV is €2.10, below its last closing price of $7.96.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 0.00 | 0.00 | 0.00 | Met | 20 |
Jun. 30 2024 | 0.02 | 0.01 | -0.01 | Missed | -200 |
Mar. 31 2024 | 0.01 | 0.01 | -0.02 | Missed | -371.4 |
Dec. 31 2023 | 0.01 | 0.00 | Missed | -140 | |
Sep. 30 2023 | -0.03 | -0.03 | 0.01 | Beat | 119.2 |
Jun. 30 2023 | -0.02 | -0.01 | 0.00 | Beat | 100 |
Mar. 31 2023 | -0.01 | -0.01 | -0.02 | Missed | -161.5 |
Dec. 31 2022 | 0.01 | 0.01 | -0.02 | Missed | -440.1 |
This summary was machine generated March 11 at 06:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments